These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 24863615)

  • 1. Temporal trends in the use of high-dose potent statins following acute coronary syndrome in Israel.
    Elis A; Pereg D; Dicker D; Gevrielov-Yusim N; Goldenberg I; Matetzky S; Kopel E; Klempfner R
    Cardiology; 2014; 128(3):266-72. PubMed ID: 24863615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy.
    Puri R; Nissen SE; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
    Eur Heart J; 2013 Nov; 34(41):3182-90. PubMed ID: 23886915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
    Heintjes EM; Penning-van Beest FJ; Plat AW; Meerding WJ; Webb K; Sturkenboom MC; Herings RM
    Pharmacotherapy; 2012 Jul; 32(7):631-41. PubMed ID: 22760692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current statin usage for patients with acute coronary syndrome undergoing percutaneous coronary intervention: multicenter survey in Korea.
    Kim MJ; Jeon DS; Gwon HC; Kim SJ; Chang K; Kim HS; Tahk SJ;
    Clin Cardiol; 2012 Nov; 35(11):700-6. PubMed ID: 22825844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy.
    Puri R; Nissen SE; Libby P; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
    Circulation; 2013 Nov; 128(22):2395-403. PubMed ID: 24043299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of high reloading ROsuvastatin and Atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of MyocArdial periprocedural necrosis. The ROMA II trial.
    Sardella G; Lucisano L; Mancone M; Conti G; Calcagno S; Stio RE; Pennacchi M; Biondi-Zoccai G; Canali E; Fedele F
    Int J Cardiol; 2013 Oct; 168(4):3715-20. PubMed ID: 23849964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: an analysis from the VOYAGER database.
    Palmer MK; Nicholls SJ; Lundman P; Barter PJ; Karlson BW
    Eur J Prev Cardiol; 2013 Dec; 20(6):1080-7. PubMed ID: 23644489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins.
    Asztalos BF; Le Maulf F; Dallal GE; Stein E; Jones PH; Horvath KV; McTaggart F; Schaefer EJ
    Am J Cardiol; 2007 Mar; 99(5):681-5. PubMed ID: 17317371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of different statins, ezetimibe/simvastatin combination on hsCRP levels in unstable angina pectoris and non-ST elevation myocardial infarction patients: a randomized trial].
    Namal E; Sener N; Ulaş T; Akçalı Z; Oztekin E; Borlu F
    Anadolu Kardiyol Derg; 2011 Dec; 11(8):703-10. PubMed ID: 22088858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study).
    Pitt B; Loscalzo J; Monyak J; Miller E; Raichlen J
    Am J Cardiol; 2012 May; 109(9):1239-46. PubMed ID: 22360820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
    Murphy SA; Cannon CP; Wiviott SD; de Lemos JA; Blazing MA; McCabe CH; Califf RM; Braunwald E
    Am J Cardiol; 2007 Oct; 100(7):1047-51. PubMed ID: 17884359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).
    Ballantyne CM; Pitt B; Loscalzo J; Cain VA; Raichlen JS
    Am J Cardiol; 2013 Feb; 111(4):506-9. PubMed ID: 23237107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between inflammation and benefits of early high-dose rosuvastatin on contrast-induced nephropathy in patients with acute coronary syndrome: the pathophysiological link in the PRATO-ACS study (Protective Effect of Rosuvastatin and Antiplatelet Therapy on Contrast-Induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention).
    Toso A; Leoncini M; Maioli M; Tropeano F; Di Vincenzo E; Villani S; Bellandi F
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1421-9. PubMed ID: 25523533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER).
    Nicholls SJ; Brandrup-Wognsen G; Palmer M; Barter PJ
    Am J Cardiol; 2010 Jan; 105(1):69-76. PubMed ID: 20102893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?
    Ara R; Pandor A; Stevens J; Rafia R; Ward SE; Rees A; Durrington PN; Reynolds TM; Wierzbicki AS; Stevenson M
    Eur J Prev Cardiol; 2012 Jun; 19(3):474-83. PubMed ID: 21460076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy.
    Gibson CM; Pride YB; Hochberg CP; Sloan S; Sabatine MS; Cannon CP;
    J Am Coll Cardiol; 2009 Dec; 54(24):2290-5. PubMed ID: 19958964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial.
    Ray KK; Cannon CP; McCabe CH; Cairns R; Tonkin AM; Sacks FM; Jackson G; Braunwald E;
    J Am Coll Cardiol; 2005 Oct; 46(8):1405-10. PubMed ID: 16226162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of high-dose statin pre-treatment and contrast-induced acute kidney injury on follow-up events in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Patti G; Leoncini M; Toso A; Maioli M; Grieco D; Colonna G; Bellandi F; Di Sciascio G
    Int J Cardiol; 2014 Jun; 174(2):440-1. PubMed ID: 24767765
    [No Abstract]   [Full Text] [Related]  

  • 19. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.
    Murphy SA; Cannon CP; Wiviott SD; McCabe CH; Braunwald E
    J Am Coll Cardiol; 2009 Dec; 54(25):2358-62. PubMed ID: 20082923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
    Cannon CP; Braunwald E; McCabe CH; Rader DJ; Rouleau JL; Belder R; Joyal SV; Hill KA; Pfeffer MA; Skene AM;
    N Engl J Med; 2004 Apr; 350(15):1495-504. PubMed ID: 15007110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.